Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection

Launched by RAFIC HARIRI UNIVERSITY HOSPITAL · Jun 30, 2015

Keywords

ClinConnect Summary

Ascertain the long term safety and efficacy of ziv-aflibercept in a large variety of ocular diseases and over a long-term after its proven safety and efficacy in the laboratory, in phase one study and in isolated case report.

Background and Significance:

Anti-VEGF therapy is currently one of the mainstay of therapy in a great number of diseases of the eye with intravitreal injections of antiVEGF being the number one procedure done in the office of an ophthalmology practice. The ophthalmic community has currently 2 very expensive antiVEGF both approved by the FDA for ocular use: Ranibizuma...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria: All conditions that require anti-VEGF therapy
• • 1. All eye conditions that require anti-VEGF therapy
• • 2. Ability to understand and sign consent form
• • 3. Ability to come for all follow-ups (2 year followup)
• • 4. Acute form of the disease only in naïve cases
• Exclusion Criteria:
• • 1. Cardiovascular, cerebrovascular or peripheral vascular event less than 3 months prior to enrollment
• • 2. Current infection in the eye such as conjunctivitis or keratitis
• • 3. Current upper respiratory tract infection
• • 4. Fever or active body infection
• • 5. Life-threatening disease with short survival
• • 6. late presentation of the disease (chronic end stage disease of the eye)
• • 7. Inability to sign informed consent
• • 8. Inability to come for followups